The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. Consequently, the Company has concluded each operating segment to be a reportable segment. The Company’s operating segments are as follows:

Oncology Innovation Platform— This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. It focuses specifically on Orascovery and Src Kinase Inhibition research platforms, and TCR-T Immunotherapy and Arginine Deprivation Therapy. This segment operates in the United States, Taiwan, Hong Kong, mainland China, the United Kingdom, and Latin America.

Global Supply Chain Platform— This operating segment includes APS and Polymed and the construction of the manufacturing facilities in Chongqing, China and Dunkirk, New York. APS is a contract manufacturing company that provides small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and for use as internal supplies to the clinical studies and commercial development of the Company’s proprietary drugs. APS also performs microbiological and analytical testing for raw material and formulated products and has expanded to manufacture and sell pharmaceutical products under Section 503B of the Compounding Quality Act within the Federal Food, Drug & Cosmetic Act (“FDCA”). Polymed is primarily in the business of marketing and selling API in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds and processing techniques, and recently completed construction of a new API manufacturing facility in Chongqing, China. The 440,000-square-foot facility is expected to commence operations in the second half of 2020. The Company has an existing API manufacturing facility in Chongqing, China, where operations were suspended as a result of the COVID-19 outbreak in China but resumed producing API in March in accordance with local regulatory guidance.

Commercial Platform— This operating segment includes APD and Athenex Oncology, which focus on the manufacturing, distribution, and sales of specialty pharmaceuticals and the pre-launch commercial activities for the Company’s proprietary drugs, respectively. This segment provides services and products to external customers based mainly in the United States.

The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, mainland China, the United Kingdom, and Latin America. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. The Commercial Platform segment operates and holds long-lived assets located in the United States. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer.

	Three Months Ended March 31,
	2020			2019
Total revenue:
Oncology Innovation Platform	$	28,387		$	144
Global Supply Chain Platform		3,714			11,339
Commercial Platform		15,542			14,675
Total revenue for reportable segments		47,643			26,158
Intersegment revenue		(708	)		(851	)
Total consolidated revenue	$	46,935		$	25,307

Intersegment revenue eliminated in the above table reflects sales from the Global Supply Chain Platform to the Oncology Innovation Platform.

	Three Months Ended March 31,
	2020		2019
Total revenue by product group:
License fees	$	28,381	$	—
Commercial product sales		17,502		20,081
API sales		1,022		4,831
Contract manufacturing revenue		23		251
Other revenue		7		144
Total consolidated revenue	$	46,935	$	25,307

Intersegment revenue is recognized by the selling segment when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger.

	Three Months Ended March 31,
	2020			2019
Net loss attributable to Athenex, Inc.:
Oncology Innovation Platform	$	(958	)	$	(27,603	)
Global Supply Chain Platform		(5,986	)		(767	)
Commercial Platform		(12,485	)		(6,863	)
Total consolidated net loss attributable to Athenex, Inc.	$	(19,429	)	$	(35,233	)

	Three Months Ended March 31,
	2020		2019
Total depreciation and amortization:
Oncology Innovation Platform	$	175	$	189
Global Supply Chain Platform		496		311
Commercial Platform		415		379
Total consolidated depreciation and amortization	$	1,086	$	879

	March 31,		December 31,
	2020		2019
Total assets:
Oncology Innovation Platform	$	156,358	$	194,183
Global Supply Chain Platform		81,930		63,598
Commercial Platform		59,499		52,151
Total consolidated assets	$	297,787	$	309,932

	Three Months Ended March 31,
	2020		2019
Total revenue:
China	$	28,513	$	386
United States		17,522		20,335
India		—		777
Austria		—		2,173
United Kingdom		—		1,023
Other foreign countries		900		613
Total consolidated revenue	$	46,935	$	25,307

	March 31,		December 31,
	2020		2019
Total property and equipment, net:
United States	$	12,467	$	11,486
China		12,149		11,667
Total consolidated property and equipment, net	$	24,616	$	23,153

Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment.

	Three Months Ended March 31,
	2020			2019
Percentage of total revenue by customer:
Customer A		60	%		0	%
Customer B		11	%		22	%
Customer C		9	%		21	%
Customer D		7	%		12	%

	March 31,			December 31,
	2020			2019
Percentage of total accounts receivable by customer:
Customer A		58	%		0	%
Customer B		14	%		45	%
Customer C		13	%		31	%
Customer D		8	%		10	%